Purpose: The INSPIRE study compared perioperative and 12-month health economic and clinical outcomes associated with hysterectomy, myomectomy, and sonography-guided transcervical fibroid ablation (TFA) using the Sonata ® system.
Introduction
Uterine fibroids, also known as leiomyomata uteri, are benign tumors of the uterus that frequently occur in women of reproductive age. Uterine fibroids may be associated with heavy menstrual bleeding, dysmenorrhea, pelvic pain, decreased quality of life, and subfertility. 1 Uterine fibroids are highly prevalent, with approximately 70% to 80% of premenopausal women likely to develop uterine fibroids prior to menopause.
Hysterectomy and myomectomy are the most commonly performed surgical interventions for the treatment of uterine fibroids. 4 Hysterectomy involves extirpation of the uterus (and generally, the cervix), with or without ovarian conservation. Myomectomy is an operation in which individual fibroids are removed, retaining the uterus and the potential for pregnancy. According to a report from the Healthcare Cost and Utilization Project, myomectomies represented about 22% of operations for uterine fibroid treatment in the US during 2013 in both inpatient and ambulatory settings, while hysterectomies constituted more than 75% of the inpatient surgeries and 67% of the hospital-based ambulatory operations. [4] [5] [6] One costeffectiveness study estimated that major complications within 30 days of surgery averaged $2,094 for either hysterectomy or myomectomy. 7 Recent studies estimated average payer costs for hysterectomy ranging from $16,184-$25,499 (2016 dollars), depending upon the procedure setting and route of surgery. 8, 9 A 2014 comparative effectiveness study of uterine fibroid treatments estimated the combined payer and patient direct cost per myomectomy to be $23,983. 10 With over two hundred thousand combined procedures performed per year, this would equate to nearly five hundred million dollars in complication costs per year for hysterectomies and myomectomies in the United States alone.
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It is useful to understand both the clinical outcomes and the related payer costs associated with emerging treatment options compared to current standards of care such as hysterectomy and myomectomy. The Sonata ® system provides a transcervical fibroid treatment (TFA) for symptomatic uterine fibroids. It is a sonography-guided, incisionless, and uterus-preserving radiofrequency ablation treatment and is approved and commercially available in Europe and the United States. Sonata utilizes a single-use radiofrequency ablation handpiece connected to a reusable intrauterine ultrasound probe, forming a single integrated treatment device designed to ablate uterine fibroids. This integration of realtime ultrasound (for imaging) with radiofrequency ablation (for treatment) in a single device, enables a gynecologist to visualize, target and ablate a greater range of fibroid types transcervically than can be approached via operative hysteroscopy. Operative hysteroscopy is limited to the treatment of intracavitary and smaller submucosal fibroids; at least in the case of submucosal fibroid, it represents a gold standard for treatment. 12 However, Sonata uses intrauterine ultrasound to image and treat all non-pedunculated fibroids.
To better understand health care resource utilization (HCRU), procedure outcomes, and associated costs, we undertook a combined prospective and retrospective cohort study comparing TFA with Sonata to hysterectomy and myomectomy.
Materials and Methods
For the TFA procedure (Sonata ® System, Gynesonics, Inc.
Redwood City, CA, USA), HCRU, along with procedural and 12-month postoperative charges, were obtained from a subset of sites participating in the SONATA pivotal Investigational Device Exemption (IDE) clinical trial. SONATA was a prospective, longitudinal, multicenter, single-arm cohort clinical trial to assess the safety and efficacy of the Sonata system in the treatment of symptomatic uterine fibroids and enrolled patients between April 2015 and October 2016. 13 Procedural and 12-month postoperative cost and outcomes data for the hysterectomy and myomectomy arms were obtained from a nationally representative administrative claims database (the Truven Health MarketScan commercial payer claims database) for the period from July 1, 2012 to June 30, 2014 as it was the most recent data available from Truven at the time of the data request. There were no specific sample size calculations due to the need to retrospectively obtain charge data from sites that had already participated in the prospective SONATA trial. It was anticipated that only some of those sites would be able to participate and that sample size for the Sonata group would be limited in this way.
Study Population
TFA arm included patients who were enrolled in the prospective clinical trial of the Sonata procedure (SONATA pivotal IDE trial) and consisted of premenopausal women 25-50 years of age, with heavy menstrual bleeding (HMB) associated with up to 10 fibroids from 1-5 cm in maximal diameter. 13 The hysterectomy and myomectomy patients included in the claims database analysis were women 25-50 years of age who reported one of the following: a claim with a uterine fibroid diagnosis on the same day as the index procedure; an inpatient claim with a uterine fibroid diagnosis at any time in the 12-month pre-index period; or at least two outpatient claims, occurring 30 days apart or more, with a uterine fibroid diagnosis at any time in the 12-month preindex period. Hysterectomy and myomectomy procedures of interest were identified using appropriate International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Disease, Tenth Revision, and Current Procedural Terminology (CPT) codes describing the procedures (Table 1) . Patients included met the additional criteria of having had no uterine fibroid treatment procedure in the 42-month pre-index period; no diagnosis associated with postmenopause in either the 42-month pre-index period or the 24-month post-index period; no diagnosis for an extrauterine pelvic mass or abdominal/pelvic malignancy in the 24-month post-index period; and 42 months of pre-index and 24 months of post-index continuous medical and pharmacy enrollment.
The Western IRB (WIRB) determined that this research was exempt from IRB approval on 9/11/2017, finding that it did not involve human subjects under 45 CFR 46.102(f). The finding was based on both the research not involving data collected specifically for the current project and the researchers not being able to ascertain the identity of individual participants.
Outcomes
The primary outcomes of interest for the Initial Comparison of Payer Costs for Sonata Relative to Standard of Care (INSPIRE) study were payer costs associated with the index procedure and the postoperative HCRUs through 12-months. The perioperative period was defined as the hospital stay for the index procedure. The postoperative period was defined as the period after discharge through 1 year. Postoperative HCRU categories included complication related HCRU, medications including opioid usage, radiology, office visits, supply costs, procedure-related complications, and subsequent procedures.
As part of the SONATA trial protocol, participating sites submitted institution billing form (UB-04) and/or provider billing form (HCFA-1500) for all charges accrued during the enrolled patients' Sonata procedure. The associated hospital outpatient payment is estimated based on Medicare 2016 Outpatient Prospective Payment System rates that would be associated with the Sonata procedure code 0404T ($5,699), which was effective January 1, 2016; all hospital outpatient services provided on the day of the procedure were bundled into one payment, as the code is a J1 status indicator. The physician payment for the TFA was based on average 2017 Medicare rates, which includes surgeon and anesthesiologist, and payments. We estimated for this study the surgeon payment (CPT code 0404T) would be comparable to that of laparoscopic radiofrequency ablation (CPT code 58674) and assigned the corresponding Medicare 2017 national payment. The anesthesiologist payment (CPT code 00852) was based on the 2016 Medicare base anesthesia unit payment (4.0). Five (5) time units (15 min increments per time unit), or 75 mins, were used to estimate the average anesthesia duration. This estimate is a conservative assessment based on the average operating room time of 77 mins for the TFA patients. This was then multiplied by the anesthesia 2016 conversion factor of $22.4426, to arrive at the total estimated payment for the anesthesiologist services. Office visits were assumed to be coded as established patients, and CPT code 99213 was used. As the Sonata procedure reimbursement is carrier dependent, payments for all hospital and physician fees were then adjusted by a Medicare-to-commercial payer ratio of 125%.
14 Prescription costs were based on RED BOOK Online (Truven Health Analytics, accessed December 2017). 15 For the hysterectomy and myomectomy arms, patientlevel charge data associated with the index procedure and 12-month postoperative HCRU data from the Truven dataset were converted to payments using a 70% charge-to-payment adjustment. 16 The robustness of the result was assessed by varying this parameter in several sensitivity analyses. For each procedure, the following were collected: inpatient and outpatient facility charges, professional service charges, complication-related charges, postoperative outpatient office visits, prescription medications including opioids, ED visits, inpatient hospitalizations, length of stay, subsequent procedures, and radiology. Several sensitivity analyses were conducted around the procedural and 12-month postoperative HCRU payment estimates. The Medicare-to-commercial payer adjustment used to estimate payments for TFA was increased to as much as 188% (from the base case of 125%) to reflect Medicare-to-commercial payer ratios reported in the literature, 17, 18 while the charge-to-payment adjustment for hysterectomy and myomectomy arms was also decreased down to 50% (from the base case of 70%), to assess the robustness of results. Payer costs for the hysterectomy and myomectomy arms were stratified by inpatient or outpatient setting, as well as by robotic-assisted status, to explore how these factors affect costs. Finally, sensitivity analyses were conducted in which the high-cost outliers, or those costs that were more than 1.5 times median, were removed from the hysterectomy and myomectomy arms.
Analysis
All analyses were conducted in Stata (version 13; StataCorp LLC, College Station, Texas). Patient characteristics were reported, and a chi-square analysis was used to determine the difference between groups. Means for total payments, payments for the index procedure and length of stay (LOS, defined as time of admission to time of discharge or time eligible to be discharged), and payments for postoperative HCRU were reported for the TFA, hysterectomy, and myomectomy procedures. The Welch t-test for unequal variances were used to compare mean facility costs between TFA and the comparators. For all comparisons, a p-value <0.05 was considered statistically significant.
Results

Patient Characteristics and LOS
In the TFA arm, 6 outpatient hospital sites from the SONATA trial participated in INSPIRE and provided billing data on 51 patients. For the comparator arms, a total of 35,463 patients who underwent hysterectomy and 8,548 patients who underwent myomectomy were included. Table 2 describes the characteristics of patients included in the study. Women undergoing treatment with the Sonata system, with a mean age of 44 (CI: 43.0-45.0) years, were older than those undergoing either a hysterectomy (42; CI: HCRU Table 3 shows the results from the 12-month postoperative HCRU review. HCRU categories included total outpatient office visits, subsequent procedure, and prescription medications (opioids and NSAIDs). As a determinant of pain control costing, 31.4% of TFA, 44.4% of hysterectomy, and 37.6% of myomectomy patients received an opioid prescription, although differences were not statistically significant. To gain further understanding of procedural outcomes and associated cost, total payments were broken down by index procedure and postoperative HCRU (Table 4) . Index procedure payments were significantly lower for TFA in comparison to both hysterectomy and myomectomy (p <0.001). For total postoperative costs, Sonata patients, on average, had significantly lower total postoperative costs than both hysterectomy and myomectomy patients (p <0.001). As shown in 
Payer Costs Procedure Costs
Results from the overall payer cost analysis are presented in Figure 1 . The mean cost to the payer for TFA with Sonata and the associated 12-month postoperative HCRU was $8,941 (CI: $8,815-$9,067), compared to $24,156 Payment Sub-Analyses Table 5 presents payer costs stratified by both the use of robotic-assistance and the site of service (inpatient or outpatient). The least-costly hysterectomy procedures are those conducted in the outpatient setting without robotic assistance (mean cost of $21,337; CI: $21,152-$21,512), while the least costly myomectomy procedures are also conducted in the outpatient setting, again without robotic assistance (mean cost of $18,896; CI: $18,488-$19,304). However, TFA continued to have significantly lower payer costs compared to these least costly comparator procedures (p <0.001).
Sensitivity Analyses
A variety of one-way and two-way sensitivity analyses altered the Medicare-to-commercial payment ratios (ranging from the base case of 125% up to 188%) and charge-to payment ratios (ranging from the base case of 70% down to 50%) to explore how market changes affect payer costs of uterine fibroid treatment ( Table 6 ). The mean payer cost for TFA rose to $13,447 (CI: $13,257-$13,637) when the Medicare-to-commercial payment ratio increased to 188%. Mean payer costs for hysterectomy and myomectomy fell to $17,254 (CI: $17,130-$17,378) and $16,274 (CI: $15,981-$16,567), respectively, when the charge-to-payment ratio for the comparator arms is reduced from 70% to 50%. However, the mean total cost difference between TFA and both hysterectomy and myomectomy remained statistically significant in each of these analyses (p <0.001), demonstrating significantly lower costs associated with TFA. Figure 2 presents payer costs when high-cost outliers are removed from the hysterectomy and myomectomy cohorts. High-cost outliers for comparator arms were identified as procedures with total costs more than 1.5 times the median, resulting in thresholds of $48,541 and $51,840 for 
Consideration of High Cost Outliers
Discussion
The results of the INSPIRE study, which examined the health economic outcomes and costs of TFA using the Sonata system compared to hysterectomy and myomectomy, showed that the cost of TFA to payers is significantly less than that of hysterectomy and myomectomy. Based on the current analysis, the adoption of the TFA procedure may lead to a 60% reduction in payer costs when compared to the current prevalent surgical treatments for uterine fibroids. In an environment of increasing health care costs, it is important to understand the outcomes and costs associated with innovative new treatment options relative to the current standard(s) of care. While the safety and effectiveness of the Sonata procedure has been verified, 13 there have yet to be published data comparing health economic outcomes, medical resource utilization, and payer costs of the procedure to the current standard treatments of hysterectomy and myomectomy. This is the first study to examine 12-month payer costs and HCRU for TFA using the Sonata system and compared to those for hysterectomy and myomectomy for treatment of uterine fibroids. One important strength of the study is that a well-defined methodology for estimating payments was utilized, with extensive sensitivity analyses performed around estimation parameters. Additionally, the hysterectomy and myomectomy populations are well represented in the study, as evidenced by the large sample sizes in these arms.
Despite these strengths, some notable limitations must be acknowledged. Because Sonata payment data were obtained from a subset of sites that participated in the clinical trial, the sample size was small. Also, as described previously, several assumptions had to be made about payments. However, it should be noted that hysterectomy and myomectomy payer costs identified in this study were consistent with other studies in the literature. 21 Fitch and colleagues found that hysterectomy costs ranged from $13,000 to $18,000, which are lower than we estimated for hysterectomy. However, their analyses only looked at costs up to 30 days, while we examined costs through 12-months. 8 They also capped readmission costs at $100,000. Our costs were closer to Bonafede et al, who found one-year hysterectomy costs to be up to $24,000. 9 Bonafede also looked at hysteroscopic myomectomy, which carried a mean cost of $17,300, considerably higher than the cost associated with TFA ($8,914).
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Conclusion
Compared to hysterectomy and myomectomy, TFA treatment with the Sonata system was associated with significantly lower index procedure cost, complication cost, and LOS, contributing to a significantly lower total payer cost through 12 months.
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